Three femtosecond laser comparisons: IntraLase FS30 comes out on top

Article

The IntraLase femtosecond FS30 laser creates a more predictable and more stable flap thickness than the Hansatome XP microkeratome (Bausch & Lomb) and the IntraLase femtosecond FS2 laser, according to research conducted by Baha Toygar and colleagues from Turkey.

The IntraLase femtosecond FS30 laser creates a more predictable and more stable flap thickness than the Hansatome XP microkeratome (Bausch & Lomb) and the IntraLase femtosecond FS2 laser, according to research conducted by Baha Toygar and colleagues from Turkey.

A prospective study of the three LASIK procedures was performed in 303 eyes of 167 patients. Each procedure was carried out by the same surgeon. The Hansatome XP microkeratome with 120 µm head was used on 92 eyes (Group A). The IntraLase FS2 15 Hertz laser was used to create a 120 µm flap in 100 eyes (Group B) and the IntraLase FS30 30 Hertz laser was used to create a 120 µm flap in 111 eyes (Group C). Flap thickness was measured by subtraction of intraoperative stromal pachymetry from intraoperative corneal pachymetry.

The mean flap thickness was 133.37±20.37 µm in Group A, 132.25±19.90 µm in Group B and 116.45±18.13 µm in Group C.

The researchers found that the IntraLase femtosecond FS30 created more predictable and stable flap thicknesses than the other two lasers. No significant differences were found between the Hansatome XP and the IntraLase FS2.

Ophthalmology Times Europe reporting from the XXIV Congress of the ESCRS, London, 9-13 September, 2006.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.